Inhibición dual de la neprilisina y el receptor de angiotensina II: nueva estrategia prometedora en el tratamiento de la enfermedad cardiovascular

Información del artículo

La inhibición de neprilisina y el bloqueo de los receptores de angiotensina II, ofrecen beneficios potenciales para el tratamiento de las enfermedades cardiovasculares. El compuesto LCZ696 es el primer fármaco en fase de estudio como inhibidor de la neprilisina y de los receptores de angiotensina. El aumento de la concentración de los péptidos natriuréticos a través de la inhibición de la neprilisina, representa un enfoque terapéutico que tiene el potencial de conferir protección cardiaca, renal y vascular. Sin embargo, diversos estudios demuestran que los beneficios clínicos de la inhibición de la neprilisina pueden ser mejor aprovechados si se inhibe simultáneamente el sistema renina-angiotensina. Esta revisión realizada en PubMed, tiene como objetivo presentar los avances prometedores en el mecanismo dual de inhibición de la neprilisina y el receptor de angiotensina II para el tratamiento de la hipertensión y la insuficiencia cardiaca.

Palabras clave:

angiotensina

hipertensión

insuficiencia cardíaca

péptidos natriuréticos

Neprilysin inhibition and angiotensin II receptor blockade offer potential benefits for the treatment of cardiovascular diseases. The compound LCZ696 is the first drug under study phase as an inhibitor of neprilysin and angiotensin receptors. The increase of the concentration of the natriuretic peptides through the inhibition of neprilysin represents a therapeutic approach which has the potential of conferring cardiac, renal and vascular protection. However, several studies show that the clinical benefits of neprilysin inhibition can be better utilized if the renin-angiotensin system is simultaneously inhibited. This review realized in PubMed aims to present the promising advances in the dual mechanism of inhibition of neprilysin and angiotensin II receptor for the treatment of hypertension and heart failure.

Keywords:

angiotensin

hypertension

heart failure

natriuretic peptides

El Texto completo está disponible en PDF

Bibliografía

[1.]

C. Deaton, E.S. Froelicher, L.H. Wu, C. Ho, K. Shishani, T. Jaarsma.

The global burden of cardiovascular disease.

J Cardiovasc Nurs, 26 (2011), pp. S5-S14

http://dx.doi.org/10.1097/JCN.0b013e318213efcf | Medline

[2.]

P.M. Kearney, M. Whelton, K. Reynolds, P. Muntner, P.K. Whelton, J. He.

Global burden of hypertension: analysis of worldwide data.

Lancet, 365 (2005), pp. 217-223

http://dx.doi.org/10.1016/S0140-6736(05)17741-1 | Medline

[3.]

Guías colombianas para el diagnóstico y tratamiento de la hipertensión arterial.

Rev Colomb Cardiol, 13 (2007), pp. 187-195

[4.]

Trial watch: dual inhibition shows promise in, hypertension.

Nat Rev Drug Discov, 9 (2010), pp. 350

http://dx.doi.org/10.1038/nrd3171 | Medline

[5.]

B. Waeber, F. Feihl.

Blood-pressure reduction with LCZ696.

The Lancet, 375 (2010), pp. 1228-1229

[6.]

H.A. Struijker-Boudier, E. Ambrosioni, H. Holzgreve, S. Laurent, G. Mancia, L.M. Ruilope, et al.

The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbiditymortality trials?.

Int J Clin Pract, 61 (2007), pp. 1592-1602

http://dx.doi.org/10.1111/j.1742-1241.2007.01302.x | Medline

[7.]

G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, et al.

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

J Hypertens, 25 (2007), pp. 1105-1187

http://dx.doi.org/10.1097/HJH.0b013e3281fc975a | Medline

[8.]

T. Unger, L. Paulis, D.A. Sica.

Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.

Eur Heart J, 32 (2011), pp. 2739-2747

http://dx.doi.org/10.1093/eurheartj/ehr253 | Medline

[9.]

D. Aronson, H. Krum.

Novel therapies in acute and chronic heart failure.

Pharmacol Ther, 135 (2012), pp. 1-17

http://dx.doi.org/10.1016/j.pharmthera.2012.03.002 | Medline

[10.]

L. Paulis, U.M. Steckelings, T. Unger.

Key advances in antihypertensive treatment.

Nat Rev Cardiol, 9 (2012), pp. 276-285

http://dx.doi.org/10.1038/nrcardio.2012.33 | Medline

[11.]

S.D. Solomon, M. Zile, B. Pieske, A. Voors, A. Shah, E. Kraigher-Krainer, et al.

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

The Lancet, 380 (2012), pp. 1387-1395

[12.]

L.M. Ruilope, A. Dukat, M. Böhm, Y. Lacourcière, J. Gong, M.P. Lefkowitz.

Bloodpressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.

The Lancet, 375 (2012), pp. 1255-1266

[13.]

J. Segura, J. Salazar, L.M. Ruilope.

Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition.

Expert Opin Investig Drugs, 22 (2013), pp. 915-925

http://dx.doi.org/10.1517/13543784.2013.797962 | Medline

[14.]

M.A. Weber.

Vasopeptidase inhibitors.

The Lancet, 358 (2001), pp. 1525-1532

[15.]

D.G. Gardner, S. Chen, D.J. Glenn, C.L. Grigsby.

Molecular biology of the natriuretic peptide system: implications for physiology and hypertension.

Hypertension, 49 (2007), pp. 419-426

http://dx.doi.org/10.1161/01.HYP.0000258532.07418.fa | Medline

[16.]

E.R. Levin, D.G. Gardner, W.K. Samson.

Natriuretic peptides.

N Engl J Med, 339 (1998), pp. 321-328

http://dx.doi.org/10.1056/NEJM199807303390507 | Medline

[17.]

J. Gu, A. Noe, P. Chandra, S. Al-Fayoumi, M. Ligueros-Saylan, R. Sarangapani, et al.

Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

J Clin Pharmacol, 50 (2010), pp. 401-414

http://dx.doi.org/10.1177/0091270009343932 | Medline

[18.]

C.Y. Lee, J.C. Burnett Jr..

Natriuretic peptides and therapeutic applications.

Heart Fail Rev, 12 (2007), pp. 131-142

http://dx.doi.org/10.1007/s10741-007-9016-3 | Medline

[19.]

S. Mangiafico, L.C. Costello-Boerrigter, I.A. Andersen, A. Cataliotti, J.C. Burnett Jr..

Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics.

Eur Heart J, 34 (2013), pp. 886-893

http://dx.doi.org/10.1093/eurheartj/ehs262 | Medline

[20.]

G.F. Baxter.

The natriuretic peptides.

Basic Res Cardiol, 99 (2004), pp. 71-75

http://dx.doi.org/10.1007/s00395-004-0457-8 | Medline

[21.]

L.R. Potter, S. Abbey-Hosch, D.M. Dickey.

Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions.

Endocr Rev, 27 (2006), pp. 47-72

http://dx.doi.org/10.1210/er.2005-0014 | Medline

[22.]

E.G. Bevan, J.M. Connell, J. Doyle, H.A. Carmichael, D.L. Davies, A.R. Lorimer, et al.

Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension.

J Hypertens, 10 (1992), pp. 607-613

Medline

[23.]

D.J. Campbell.

Vasopeptidase inhibition: a double-edged sword?.

Hypertension, 41 (2003), pp. 383-389

http://dx.doi.org/10.1161/01.HYP.0000054215.71691.16 | Medline

[24.]

J.C. Burnett Jr..

Vasopeptidase inhibition: a new concept in blood pressure management.

J Hypertens Suppl, 17 (1999), pp. S37-S43

Medline

[25.]

J.B. Kostis, M. Packer, H.R. Black, R. Schmieder, D. Henry, E. Levy.

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial.

Am J Hypertens, 17 (2004), pp. 103-111

Medline

[26.]

G.F. Mitchell, J.L. Izzo Jr., Y. Lacourciere, J.P. Ouellet, J. Neutel, C. Qian, et al.

Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study.

Circulation, 105 (2002), pp. 2955-2961

Medline

[27.]

R.M. Fryer, J. Segreti, P.N. Banfor, D.L. Widomski, B.J. Backes, C.W. Lin, et al.

Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema.

Br J Pharmacol, 153 (2008), pp. 947-955

http://dx.doi.org/10.1038/sj.bjp.0707641 | Medline

[28.]

F.H. Messerli, J. Nussberger.

Vasopeptidase inhibition and angio-oedema.

Lancet, 356 (2000), pp. 608-609

http://dx.doi.org/10.1016/S0140-6736(00)02596-4 | Medline

[29.]

M. Cicardi, L.C. Zingale, L. Bergamaschini, A. Agostoni.

Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment.

Arch Intern Med, 164 (2004), pp. 910-913

http://dx.doi.org/10.1001/archinte.164.8.910 | Medline

[30.]

L. Feng, P.H. Karpinski, P. Sutton, Y. Liu, D.F. Hook, B. Hu, et al.

LCZ696: a dual-acting sodium supramolecular complex.

Tetrahedron Letters, 53 (2012), pp. 275-276

[31.]

M.J. Bloch, J.N. Basile.

Combination angiotensin receptor blocker-neutral endopeptidase inhibitor provides additive blood pressure reduction over angiotensin receptor blocker alone.

J Clin Hypertens (Greenwich), 12 (2010), pp. 809-812

[32.]

C.S. Lam, E. Donal, E. Kraigher-Krainer, R.S. Vasan.

Epidemiology and clinical course of heart failure with preserved ejection fraction.

Eur J Heart Fail, 13 (2011), pp. 18-28

http://dx.doi.org/10.1093/eurjhf/hfq121 | Medline

[33.]

B.M. Mearns.

Phase II PARAMOUNT trial of LCZ696.

Nat Rev Cardiol, 9 (2012), pp. 612

http://dx.doi.org/10.1038/nrcardio.2012.135 | Medline

[34.]